Skip to main content
Log in

Klug-entscheiden-Empfehlungen in der Rheumatologie

Ein Jahr nach der Erstveröffentlichung

Choosing wisely recommendations in rheumatology

One year after their first publication

  • Schwerpunkt: Klug entscheiden
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Knapp ein Jahr nach Veröffentlichung der Klug-entscheiden-Empfehlungen (KEE) in der Rheumatologie zeigt sich, dass Fach- und Laienpresse, Medien der Selbsthilfegruppen, Onlinemedien und Fortbildungskongresse das Thema aufgegriffen haben. Somit konnte ein breites Zielpublikum erreicht werden. Zwischenzeitlich wurden auch Leitlinien neu publiziert oder aktualisiert, die rheumatologische KEE aufgreifen. KEE sind geeignet, Eingang in klinische Standard Operating Procedures oder Handlungsempfehlungen zu finden.

Abstract

Almost 1 year after publication of the Choosing wisely recommendations (“Klug-entscheiden-Empfehlungen,” KEE) for rheumatology, it is evident that they have found their way into specialist and lay publications, the media used by self-help groups, online media, and continuing education congresses. As such, a broad target audience has been reached. In the meantime, newly established or updated guidelines have been published which incorporate the KEE for rheumatology. The KEE provide a gateway into clinical Standard Operating Procedures or recommendations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Auwarter PG, Bakken JS, Dattwyler RS et al (2011) Antiscience and ethical concerns associated with advocacy of Lyme disease. Lancet Infect Dis 11:713–719

    Article  Google Scholar 

  2. Benvenuti F et al (2015) Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythemsosis: a literature review. Expert Opin Drug Saf 14:1373–1385

    Article  PubMed  Google Scholar 

  3. de Vries MK, van Eijk IC, van der Horst-Bruinsma IE et al (2009) Erythrocyte sedimentation rate, C‑reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 61:1484–1490

    Article  PubMed  Google Scholar 

  4. Dixon WG, Abrahamowicz M, Beauchamp ME et al (2012) Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 71:1128–1133

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Dougados M, Soubrier M, Antunez A et al (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62–68

    Article  PubMed  Google Scholar 

  6. Feder HM, Johnson BJB, O’Connell S et al (2007) A critical appraisal of „Chronic Lyme Disease“. N Engl J Med 357:1422–1430

    Article  CAS  PubMed  Google Scholar 

  7. Fiehn C, Herzer P, Holle J et al (2016) Klug entscheiden in der Rheumatologie. Dtsch Arztebl 113(24):A-1154

    Google Scholar 

  8. Gabriel SE, Sunku J, Salvarani C, O’Fallon WM, Hunder GG (1997) Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 40:1873–1878

    Article  CAS  PubMed  Google Scholar 

  9. Goldacker S, Gause AM, Warnatz K, Kommission Pharmakotherapie der DGRh (2013) Impfung bei erwachsenen Patienten mit chronisch entzündlichen rheumatischen Erkrankungen. Z Rheumatol 72:690–704

    Article  CAS  PubMed  Google Scholar 

  10. Hayashi N et al (2008) Prevalence of disease specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period. Mod Rheumatol 18:153–160

    Article  CAS  PubMed  Google Scholar 

  11. Hensor EMA, Emery P, Bingham SJ, Conaghan PG, YEAR Consortium (2010) Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): can they be reduced? Rheumatology 49:1521–1529

    Article  PubMed  Google Scholar 

  12. Jarvik JG, Gold LS, Comstock BA et al (2015) Association of early imaging for back pain with clinical outcomes in older adults. JAMA 313(11):1143–1153

    Article  CAS  PubMed  Google Scholar 

  13. Kiltz U, Braun J. Deutsche Gesellschaft für Rheumatologie (DGRh) (2013) S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen. http://www.awmf.org/uploads/tx_szleitlinien/060-003l_S3_Axiale_Spondyloarthritis_Morbus_Bechterew_2013-11.pdf. Zugegriffen: 18. Aug. 2016

    Google Scholar 

  14. Kiltz U, Alten R, Fleck M et al (2016) Gichtarthritis (fachärztlich) Evidenzbasierte Leitlinie der Deutschen Gesellschaft für Rheumatologie (DGRh). Langfassung zur S2e- Leitlinie. AWMF-Leitlinien Register Nummer: 060/005, Entwicklungsstufe: S2e, Stand 30.04.2016. http://dgrh.de/fileadmin/media/Praxis___Klinik/Leitlinien/Gicht_LL.pdf. Zugegriffen: 2. Febr. 2017

    Google Scholar 

  15. Landewe RBM, Günther KP, Lukas C et al (2010) EULAR/EFORT recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee. Ann Rheum Dis 69:12–19

    Article  CAS  PubMed  Google Scholar 

  16. Lakomek H‑J, Lakomek M, Specker C (2016) Klug entscheiden in der Rheumatologie, Indikationsqualität im Fokus. Arthritis + Rheum 36(6):402–406

    Google Scholar 

  17. Lindqvist UR, Alenius GM, Husmark T, Theander E, Holmström G, Larsson PT, Psoriatic Arthritis Group of the Society for Rheumatology (2008) The Swedish early psoriatic arthritis register – 2‑year followup: a comparison with early rheumatoid arthritis. J Rheumatol 35:668–673

    PubMed  Google Scholar 

  18. Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 52:53–61

    Article  CAS  Google Scholar 

  19. Maillefert JF et al (1997) Prevalence of ANCA in a hospitalized elderly French population. Clin Exp Rheumatol 15:603–607

    CAS  PubMed  Google Scholar 

  20. Morgan MD et al (2009) Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 60:3493–3500

    Article  PubMed  Google Scholar 

  21. Mukhtyar C, Guillevin L, Cid MC, European Vasculitis Study Group et al (2009) EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68:318–323

    Article  CAS  PubMed  Google Scholar 

  22. Nationale Versorgungsleitlinie (NVL) Kreuzschmerz, Kurzfassung, Version 1.2

  23. Nationale VersorgungsLeitlinie (NVL) (2017) Nicht-spezifischer Kreuzschmerz, Langfassung. 2. Auflage, Version 1, AWMF-Register-Nr.: nvl-007

  24. Neogi T, Jansen TLThA, Dalbeth N et al (2015) 2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheumatol 67:2557–2568

    Article  PubMed  PubMed Central  Google Scholar 

  25. Nishimura K, Sugiyama D, Kogata Y et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808

    Article  PubMed  Google Scholar 

  26. Pieringer H et al (2012) Rheumatoid arthritis is an independent risk factor for an increased augmentation index regardless of the coexistence of traditional cardiovascular risk factors. Semin Arthritis Rheum 42:17–22

    Article  PubMed  Google Scholar 

  27. Pressemeldung der Deutschen Gesellschaft für Rheumatologie (2016) Klug entscheiden: DGRh-Empfehlungen. Akt Rheumatol 41:274

    Google Scholar 

  28. Semb AG et al (2014) Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice. Ann Rheum Dis 73:1284–1288

    Article  PubMed  Google Scholar 

  29. Shi W et al (1990) Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 20:231–234

    Article  CAS  PubMed  Google Scholar 

  30. Sigal LH (2011) Musculoskeletal features of Lyme disease: understanding the pathogenesis of clinical findings helps make appropriate therapeutic choices. J Clin Rheumatol 17:256–265

    Article  PubMed  Google Scholar 

  31. Stanek G, Fingerle V, Hunfeld KP et al (2011) Lyme borreliosis: clinical case definitions for diagnosis and management in Europe (European Union Concerted Action on LB). Clin Microbiol Infect 17:69–79

    Article  CAS  PubMed  Google Scholar 

  32. Taylor TH, Mecchella JN, Larson RJ et al (2012) Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med 125(11):1126–1134

    Article  CAS  PubMed  Google Scholar 

  33. Terkeltaub RA et al (2010) High versus low dosing of oral colchicine for early acute gout flare: Twenty-four–hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62(4):1060–1068

    Article  CAS  PubMed  Google Scholar 

  34. van Assen S et al (2011) EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70:414–422

    Article  PubMed  Google Scholar 

  35. Robert Koch-Institut (2016) Impfkalender (Standardimpfungen) für Säuglinge, Kinder, Jugendliche und Erwachsene. www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Impfempfehlungen_node.html;jsessionid=02B30769BEA061CA378D98E106C8F 187.2_cid390. Zugegriffen: 27.04.2017

    Google Scholar 

  36. Robert Koch-Institut (2016) Empfehlungen der Ständigen Impfkommission. www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Aktuelles/Impfkalender.pdf?__blob=publicationFile. Zugegriffen: 27.04.2017

    Google Scholar 

  37. Zhang W, Doherty M, Pascual E et al (2006) EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 65:1301–1311

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Zhang W, Doherty M, Bardin T et al (2011) European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 70:563–570

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E. Märker-Hermann.

Ethics declarations

Interessenkonflikt

E. Märker-Hermann und A.J. Voormann geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

U.R. Fölsch, Kiel

M. Hallek, Köln

G. Hasenfuß, Göttingen

E. Märker-Hermann, Wiesbaden

C.C. Sieber, Nürnberg

Teile dieses Beitrags wurden bereits veröffentlicht in Fiehn C, Herzer P, Holle J et al. (2016) Klug entscheiden … in der Rheumatologie. Dtsch Arztebl 113(24)E. Märker-Hermann und A.J. Voormann für die Deutsche Gesellschaft für Rheumatologie (DGRh)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Märker-Hermann, E., Voormann, A.J. Klug-entscheiden-Empfehlungen in der Rheumatologie. Internist 58, 580–584 (2017). https://doi.org/10.1007/s00108-017-0247-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-017-0247-7

Schlüsselwörter

Keywords

Navigation